Piedimonte S, et al. - The prevalence, as well as results of occult tubal carcinoma in BRCA mutation carriers and high-risk patients receiving risk-reducing salpingo-oophorectomy, was estimated via a systematic review of the literature. Between 1946 and March 2019, researchers explored OVID MEDLINE, EMBASE, and ClinicalTrials.gov to identify the relevant data. Data were obtained and recorded in an Excel database. Between 2002 and 2019, risk-reducing salpingo-oophorectomy was performed on 6,283 patients: 2,894 BRCA1 cases, 1,579 BRCA2 cases, and 1,810 cases with high-risk based on family history. Of these, 75 patients received a diagnosis of occult tubal carcinoma at the time of operation. At a median age of 53.2 years, the pooled prevalence was reported to be 1.2%. Overall, findings revealed significant potential for recurrence of occult tubal carcinomas detected at risk-reducing salpingo-oophorectomy in high-risk patients and BRCA mutation carriers, despite the frequent use of postoperative chemotherapy.